Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
Idursulfase
Genzyme Australasia Pty Ltd
Medicine Registered
VERSION: ELA ANZ CMI A1208-01 SUPERCEDES: ELA ANZ CMI A0804-01 COMMERCIAL Page 1 of 3 ELAPRASE ® _ _ Idursulfase 6 mg/3 mL, Concentrate for Solution for Infusion CONSUMER MEDICINE INFORMATION _ _ WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Elaprase. It does not contain all the available information about Elaprase. It does not take the place of talking to your doctor or a trained health care professional. All medicines have risks and benefits. Your doctor has weighed the risks of you or your child having Elaprase against the benefits they expect it will have. IF YOU HAVE ANY CONCERNS ABOUT THIS MEDICINE, ASK YOUR DOCTOR OR NURSE. KEEP THIS LEAFLET. You may need to read it again. WHAT ELAPRASE IS USED FOR Elaprase is used as enzyme replacement therapy to treat Hunter syndrome, a rare genetic disease in which an enzyme called iduronate- 2-sulfatase is missing or the level of the enzyme is lower than normal. Hunter syndrome generally occurs in males and rarely in females. Elaprase is available only with a doctor’s prescription. Only your or your child’s treating doctor can start the treatment and supervise the ongoing treatment. Elaprase is to be given only to the person for whom it has been prescribed. _ _ _ _ _ _ _ _ _HOW IT WORKS _ Patients with Hunter syndrome do not produce enough of their own enzyme, iduronate-2-sulfatase. The reduced iduronate-2-sulfatase levels in patients result in the accumulation of substances called glycosaminoglycans (GAG), predominantly dermatan sulphate and heparan sulphate, in a number of cell types and tissues. Elaprase is an enzyme Read the complete document
VERSION: ELA ANZ PI A1207-01 SUPERCEDES: ELA ANZ PI A1107-01 COMMERCIAL Page 1 of 13 PRODUCT INFORMATION ELAPRASE ® NAME OF THE MEDICINE ELAPRASE (idursulfase) 6 mg/3 mL concentrate for intravenous solution for infusion. DESCRIPTION ELAPRASE (idursulfase) is a purified form of the lysosomal enzyme, iduronate-2-sulfatase. Idursulfase is produced by recombinant DNA technology in a human cell line providing a human glycosylation profile. Idursulfase is a 525 amino acid glycoprotein with 8 _N_-linked glycosylation sites that are occupied by complex, hybrid and high-mannose type oligosaccharide chains. Idursulfase has a molecular weight of approximately 76 kD. ELAPRASE, for intravenous infusion, is supplied as a sterile, aqueous, clear to slightly opalescent colourless solution that must be diluted prior to administration in 0.9% Sodium Chloride for Injection. The solution in each vial contains an idursulfase concentration of 2 mg/mL at a pH of approximately 6. The extractable volume of 3 mL from each vial provides 6 mg idursulfase, 24.0 mg sodium chloride, 6.75 mg sodium phosphate monobasic monohydrate, 2.97 mg sodium phosphate dibasic heptahydrate and 0.66 mg polysorbate 20. ELAPRASE does not contain preservatives; vials are for single use only. PHARMACOLOGY MECHANISM OF ACTION Hunter syndrome (Mucopolysaccharidosis II, MPS II) is an X-linked recessive disease caused by insufficient levels of the lysosomal enzyme iduronate-2-sulfatase (I2S). I2S functions to catabolise the glycosaminoglycans (GAG) dermatan sulphate and heparan sulphate by cleavage of oligosaccharide-linked sulphate moieties. Due to the missing or defective I2S enzyme in patients with Hunter syndrome, GAG progressively ac Read the complete document